US Patent Issued to Albert Einstein College of Medicine on April 1 for "BTNL9 and ERMAP as novel inhibitors of the immune system for immunotherapies" (New York Inventors)

ALEXANDRIA, Va., April 2 -- United States Patent no. 12,263,203, issued on April 1, was assigned to Albert Einstein College of Medicine (Bronx, N.Y.).

"BTNL9 and ERMAP as novel inhibitors of the immune system for immunotherapies" was invented by Xingxing Zang (New York) and Kaya Ghosh (Bronx, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are methods of treating a tumor in a subject with a BTNL9-binding antibody. Also provided are methods of treating a tumor in a subject with an ERMAP-binding antibody. A fusion protein comprising a BTNL9 or ERMAP and related compositions and encoding nucleic acids are also provided."

The patent was filed on May 5, 2020, under Application No. 16/867,500.

*For ...